Molecular Formula | C13H10BrCl2FN2O |
Molar Mass | 380.04 |
Density | 1.643 |
Melting Point | 107.0 to 111.0 °C |
Boling Point | 423.4±40.0 °C(Predicted) |
Appearance | powder to crystal |
Color | White to Light yellow to Light orange |
pKa | 5.55±0.10(Predicted) |
Storage Condition | under inert gas (nitrogen or Argon) at 2–8 °C |
Use | This product is for scientific research only and shall not be used for other purposes. |
Introduction | [5-bromo-3-[(1R)-(2, 6-dichloro-3-fluorophenyl) ethoxy] pyridin-2-yl] Amine is an intermediate of Crizotinib, Crizotinib it is a multi-target protein kinase inhibitor developed by Pfizer that inhibits ATP competition of Met/ALK/ROS. In patients with tumors with abnormal ALK, ROS, and MET kinase activity, respectively, the clinical efficacy of crizotinib was demonstrated in humans. It caused a sensation after being launched in the United States in 2011. The inventor is a Chinese scientist, Dr. Cui Jingrong (USpatent7858643), who won the 38th Annual American National Inventor Award. |
Use | [5-bromo-3-[(1R)-(2, 6-dichloro-3-fluorophenyl) ethoxy] pyridin-2-yl] is a useful research chemical. |
Application | [5-bromo-3-[(1R)-(2, 6-dichloro-3-fluorophenyl) ethoxy] pyridin-2-yl] amine can be used as an intermediate of crizotinib in the process of chemical and pharmaceutical research and development, crizotinib is used to treat anaplastic lymphoma kinase (ALK)-positive locally advanced and metastatic non-small cell lung cancer (NSCLC). Crizotinib in the treatment of ALK-positive non-small cell lung cancer has an objective response rate of 60% and a progression-free survival of 8-10 months, which significantly improves and prolongs overall survival compared with chemotherapy. |
crizotinib intermediate | [5-bromo-3-[(1R)-(2, 6-dichloro-3-fluorophenyl) ethoxy] pyridin-2-yl] Amine is an intermediate of Crizotinib, Crizotinib it is a multi-target protein kinase inhibitor developed by Pfizer that inhibits ATP competition of Met/ALK/ROS. In patients with tumors with abnormal ALK, ROS, and MET kinase activity, respectively, the clinical efficacy of crizotinib was demonstrated in humans. It caused a sensation after being launched in the United States in 2011. The inventor is a Chinese scientist Dr Cui Jingrong (US patent 7858643), who won the 38th Annual American National Inventor Award. Indications for the treatment of anaplastic lymphoma kinase (ALK)-positive locally advanced and metastatic non-small cell lung cancer (NSCLC). [Clinical effect] crizotinib in the treatment of ALK-positive non-small cell lung cancer objective response rate of 60%, progression-free survival of 8-10 months, compared with chemotherapy significantly improved and prolonged overall survival. |